BioSpace News Archive

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.

UroGen Pharma Ltd. today announced that it will report fourth quarter and full-year 2022 financial results on Thursday, March 16, 2023, prior to the open of the stock market.

Alpha Tau Medical Ltd. reported full year 2022 financial results and provided a corporate update.

CytoSorbents Corporation today reported financial and operating results for the quarter and year ended December 31, 2022 and provides its 2023 outlook.

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2022 on Tuesday, March 21, 2023 after market close.

Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.

Catalent, Inc. today announced that members of its executive leadership team will participate at two upcoming investor conferences.

Nemaura Medical, Inc. today announced that on February 23, 2023, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022.

Vernagen, LLC, an Atlanta-based biotech company (“Vernagen”) focuses on the preclinical and clinical development of mRNA-based vaccines and therapeutic biologics, exchanged a letter of intent (LOI) on March 3, 2023, with the U.S. Centers for Disease Control and Prevention (CDC) for collaborative research and development of a Heartland virus mRNA vaccine.